Cannabis Law Report

DECEMBER 14, 2021

–(BUSINESS WIRE)– #IGC –(NYSE American: IGC), India Globalization Capital, Inc. (“IGC” IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease.

Clinical Trials 40

Clinical Trials Safety Data Patients 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

DECEMBER 2, 2021

–(BUSINESS WIRE)– #Alzheimers –(NYSE American: IGC), India Globalization Capital, Inc. IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The details of a clinical trial process in general are documented in IGC’s annual report.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

AUGUST 3, 2021

TORONTO–( BUSINESS WIRE )– Cybin Inc. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. RADNOR, Pa.–(BUSINESS

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes.

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

SEPTEMBER 13, 2021

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. in the blood. MYMD-1 is designed to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging lifespan. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

AUGUST 25, 2021

TORONTO–(BUSINESS WIRE)– $HUGE #RestoreFSD –FSD Pharma Inc. Founded in 2020, Lucid is developing novel molecules and combinations with the goal of addressing Total Brain Health and targeting some of the most challenging neurodegenerative diseases, such as Multiple sclerosis, and other Brain conditions.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

JULY 26, 2021

Tyle brings over 35 years of experience in the pharmaceutical industry, with over 37 years in senior executive leadership positions encompassing research and development, clinical development, manufacturing, regulatory, business development and operations as well as roles as a board director and scientific advisory board member.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

SpeedWeed

MARCH 30, 2021

Business Cann first reported on the development of the ‘Patient Registry for Cannabis-Based Products’, last year and the NHS has confirmed it will launch on April 1. ( Anthony Ordman is Honorary Medical Director of Integro Medical Clinics – one of the 20-plus private clinics to have emerged since the law change in 2018.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. June 30, 2021. .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

AUGUST 19, 2021

Faced with booming sales, professor Sagnik Bhattacharyya, who researches psychotic and substance abuse disorders at King’s College London, says clinical trials are needed. “A change in policy to open up this valuable market and allow production will enable UK businesses to make the most of this global opportunity.”

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

AUGUST 17, 2021

DUBLIN–(BUSINESS WIRE)–The “Respiratory Health Management Technology Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. Therapeutic Medical Devices are Preferred by Physicians and Patients for Acute and Chronic Respiratory Conditions. The Strategic Imperative. Research Scope.

Research and Development 76

Research and Development Clinical Trials Concentrates Patients 76

Cannabis Law Report

JUNE 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. On a Trip: LSD (Lysergic Acid Diethylamide).

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S.

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 2, 2021

SAN DIEGO–(BUSINESS WIRE)– Radicle Science , a transformative healthtech B-corp validating natural products for the first time, announces the launch of the Radicle ACES (Advancing CBD Education and Science) study. brands, including Lord Jones. We are delighted to have Lord Jones involved in the Radicle Sciences’ ACES study.

CBD 81

CBD Data Sleep Clinical Trials 81

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). This post is dedicated to clearing up some of the confusion behind ketamine clinic set-up and operation. .”

Therapy 102

Therapy Legalization Chronic Pain DEA 102

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

MAY 25, 2023

Regardless of which road you go down to treat mental health disorders or another type of medical condition, it’s imperative that you consult with a healthcare professional beforehand. ” When used recreationally as a party drug, ketamine is normally snorted in the form of a crystallized powder.

Medicine 98

Medicine Blood Pressure Therapy Clinical Trials 98

Cannabis Law Report

JUNE 24, 2022

The legislation from Senate President Nicholas Scutari (D), who has long championed cannabis reform in the Garden State, would further create a system of licensed businesses to provide psilocybin services in supervised settings. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 12, 2021

Business Cann Report. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

JULY 28, 2021

We look forward to providing continued updates on our intellectual property, research, clinical, regulatory and manufacturing activities for PD-001; our novel oral formulation of cepharanthine, with the aim of working towards a first-in-human, proof-of-concept clinical trial under an FDA IND approval.” ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JULY 7, 2021

Company plans to initiate Phase II trial with a leading academic institution. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges to anyone operating in the space.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

JANUARY 12, 2022

. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. ” Gb Sciences’ intellectual property portfolio includes five U.S.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. On March 5, 2019, the U.S. Schedule I.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

OCTOBER 13, 2021

Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health conditions,” said Doug Drysdale, the company’s CEO. Vigorous scientific research and clinical trials are needed. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JULY 9, 2021

The Index is designed to provide exposure to the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S.

Data 105

Data Clinical Trials Decriminalization Hemp 105